|
|
Volumn 4, Issue 3, 2001, Pages 212-216
|
|
Implications of the appraisal function of the National Institute for Clinical Excellence (NICE)
|
|
Author keywords
Economic evaluation; NICE; Pharmaceuticals; Technology assessment
|
|
Indexed keywords
DRUG;
INFLUENZA VACCINE;
STATINE DERIVATIVE;
BIOMEDICAL TECHNOLOGY ASSESSMENT;
CONFERENCE PAPER;
DRUG CONTROL;
DRUG COST;
ECONOMIC EVALUATION;
HEALTH CARE ORGANIZATION;
HEALTH CARE QUALITY;
METHODOLOGY;
NATIONAL HEALTH SERVICE;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
|
|
EID: 0034933416
PISSN: 10983015
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1524-4733.2001.43079.x Document Type: Conference Paper |
|
Times cited : (18)
|
|
References (1)
|
